Fulvestrant prodrug
Fulvestrant prodrugs with enhanced water solubility address the low bioavailability and administration challenges of fulvestrant, offering improved treatment efficacy and patient comfort.
JP7653092B2Active Publication Date: 2025-03-28KASHIV BIOSCIENCES LLC
8 Cites 0 Cited by
Patent Information
- Application Number
- JP2023191446
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-18
- Filing Date
- 2023-11-09
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2039-05-24
AI Technical Summary
Technical Problem
Fulvestrant, a treatment for hormone receptor-positive metastatic breast cancer, faces challenges due to its low solubility and bioavailability, leading to poor release profiles and painful injections when administered intramuscularly.
Method used
Development of fulvestrant prodrugs with improved water solubility, achieved by introducing substituents into the phenolic hydroxyl group, which enhances bioavailability and allows for easier administration.
Benefits of technology
The fulvestrant prodrugs exhibit significantly higher water solubility, leading to improved bioavailability and potentially more effective treatment regimens with reduced dosing frequency and improved patient comfort.
✦ Generated by Eureka AI based on patent content.
Abstract
To provide pharmaceutical compositions of fulvestrant prodrugs.SOLUTION: The present invention provides pharmaceutical compositions comprising at least one of fulvestrant prodrugs of formula II, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof, and pharmaceutically acceptable excipients.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art